Elanco Raises 2026 Outlook on Strong Q1 Performance, Innovation Momentum
Event summary
- Elanco reported Q1 2026 revenue of $1.37B, up 15% YoY, with 10% organic constant currency growth.
- Adjusted EBITDA rose 21% YoY to $334M, with an adjusted EBITDA margin of 24.5%.
- Elanco raised its full-year revenue guidance to $5.01B–$5.085B (up from $4.95B–$5.02B) and adjusted EBITDA guidance to $975M–$1.005B (up from $955M–$985M).
- Key products like Zenrelia and Credelio Quattro drove market share gains and blockbuster status.
- Elanco completed the acquisition of AHV International on April 30, 2026.
The big picture
Elanco's strong Q1 2026 results reflect its innovation-led strategy, with key products driving market share gains and revenue growth. The company's raised full-year guidance underscores its confidence in sustaining momentum in the durable animal health industry. The acquisition of AHV International further bolsters its portfolio, positioning Elanco for continued expansion in both pet and farm animal health markets.
What we're watching
- Product Momentum
- How Elanco's innovation pipeline, including Zenrelia and Credelio Quattro, will sustain market share gains and revenue growth.
- Financial Discipline
- Whether Elanco can maintain its improved net leverage ratio target of 3.0x–3.2x while investing in growth initiatives.
- Integration Success
- The pace at which Elanco integrates AHV International and realizes synergies from the acquisition.
Related topics